Spherix Global Insights has announced the launch of its latest Market Dynamix™ service, PD-1 Inhibition in Solid Tumors (US) 2025, providing an in-depth analysis and advisory services for the evolving ...

Guardant Health posts strong Q3 results and lifts outlook. See insights on GH stock's growth, financials, and what’s driving ...

Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...

RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the third quarter ended September 30, 2025, and ...

Oral therapy showed dose-dependent increases in progranulin protein levels in both plasma and cerebrospinal fluid; >95% mean increase in progranulin levels in CSF, compared to baseline; favorable ...

Innovations like endoscopic imaging, AI-enhanced tools, and minimally invasive therapies are reshaping patient care. Despite challenges like public awareness gaps and cost barriers, strategic ...

Full year 2025 net product revenue guidance was raised to $4.23 billion to $4.32 billion, with Jakafi guidance increased to $3.05 billion to $3.075 billion. Tray affirmed, "We maintain our prior OpEx ...

An RNAi based genetic screen and subsequent analyses reveal how dyneins and small GTPases coordinate autophagosome positioning at the ncMTOC in fat cells, advancing understanding of autophagic vesicle ...

THIS AUTUMN, Paris, France, hosted the 34ᵗʰ annual European Academy of Dermatology and Venereology (EADV) Congress.

In addition, preliminary blinded aggregate safety data from the first 61 patients with a median follow-up of greater than 12 months may suggest improvements in both hematologic and non-hematologic ...